A Randomized, Double-blind, Placebo- and Active-controlled Parallel-group Multi-center Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines
Latest Information Update: 21 Oct 2024
At a glance
- Drugs YY-001 (Primary) ; Botulinum-Toxin-A
- Indications Glabellar lines
- Focus Registrational; Therapeutic Use
- Sponsors Chongqing Claruvis Pharmaceutical
Most Recent Events
- 21 Oct 2024 New source identified and integrated China Drug Trials (CTR20233901).
- 19 Jul 2024 New trial record